Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
The presence of a gBRCA-PV is associated with a higher risk of MDS-pCT and possibly of myeloid neoplasms after PARPi in patients with aHGOC who received PARPi, especially in the setting of recurrent disease.
Authors
- Enrico Derenzini (ORCID: https://orcid.org/0000-0002-7154-8140)
- Mariateresa Lapresa
- Eleonora Nicolò (ORCID: https://orcid.org/0000-0001-5042-6550)
- Silvia Derio
- Dario Trapani (ORCID: https://orcid.org/0000-0003-1672-9560)
- G. Curigliano
- Luca Boscolo Bielo (ORCID: https://orcid.org/0000-0003-1026-3923)
- Gloria Pellizzari (ORCID: https://orcid.org/0009-0002-5733-2316)
- Marta Mongillo (ORCID: https://orcid.org/0009-0004-4960-7759)
- Carmine Valenza (ORCID: https://orcid.org/0000-0003-1150-0345)
- Federica Gigli (ORCID: https://orcid.org/0000-0001-5786-8183)
- Jalissa Katrini (ORCID: https://orcid.org/0009-0003-1405-0586)
- Grazia Castellano (ORCID: https://orcid.org/0000-0003-2147-1672)
- Lorenzo Guidi (ORCID: https://orcid.org/0009-0002-6618-8598)
- Laura Boldrini (ORCID: https://orcid.org/0009-0006-0607-2154)
- Nicoletta Colombo (ORCID: https://orcid.org/0000-0003-2225-715X)
- Gabriella Parma (ORCID: https://orcid.org/0000-0002-2150-0448)
Institutions
- University of Milan (IT)
- European Institute of Oncology (IT)
- University of Milano-Bicocca (IT)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103685
- Citations
- 6
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.70